FierceBiotech5d
Denali eyes approval after Hunter syndrome drug clears safety measures, reduces biomarkers in open-label study
After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...
Denali Therapeutics (DNLI) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...
Denali Therapeutics (NASDAQ:DNLI) Price Target Cut to $40.00 by Analysts at The Goldman Sachs Group
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...